A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each
two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of
patients, those whose tumor has a documented T790M mutation, and those without this mutation.
All patients will receive repeated cycles of dacomitinib until disease progression,
occurrence of unacceptable toxicity, or other withdrawal criteria are met.